RXi to Acquire Peptide Immunotherapy Firm Apthera

The deal gives RXi a late-stage peptide immunotherapy for breast cancer and marks a shift in strategy that nudges the company from its previous focus as a pure-play RNAi shop.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.